SEC Tracker
Get the app

Senti Biosciences Holdings SNTI

Senti Biosciences Holdings enters CVR agreement

Item 1.01 Enters material agreement, Item 1.02 Ends material agreement, Item 2.01 Completes acquisition or sale

Form
8-K
Filed
Importance
Major
  1. CVR Agreement dated Oct 21, 2026
  2. Milestone payments up to $60M based on Product success
  3. CVRs issued to stockholders and option holders

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Senti Biosciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  2. Cue Biopharma CUE public float $52M, Jun 30, 2025
  3. Fitlife Brands FTLF public float $51M, Jun 30, 2025
  4. Immucell ICCC public float $51M, Jun 30, 2025
  5. iBio IBIO public float $58M, Dec 31, 2025